# Dexmedetomidine for Continuous Sedation

> **NCT00226785** · PHASE3 · TERMINATED · sponsor: **Orion Corporation, Orion Pharma** · enrollment: 900 (—)

## Conditions studied

- Conscious Sedation

## Interventions

- **DRUG:** Dexmedetomidine

## Key facts

- **NCT ID:** NCT00226785
- **Lead sponsor:** Orion Corporation, Orion Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-10
- **Primary completion:** —
- **Final completion:** 2006-07
- **Target enrollment:** 900 (—)
- **Last updated:** 2006-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00226785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00226785, "Dexmedetomidine for Continuous Sedation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00226785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*